异甘草酸镁联合恩替卡韦治疗慢性乙型病毒性肝炎的临床疗效及对患者肝功能指标的影响

Clinical Efficacy of Magnesium Isoglycyrrhizinate Combined with Entecavir in the Treatment of Chronic Hepatitis B and Its Influence on Liver Function Indicators

目的探讨异甘草酸镁联合恩替卡韦治疗慢性乙型病毒性肝炎的临床疗效及对患者肝功能指标的改善作用。方法选择2018年1月—2022年12月南京市六合医院收治的慢性乙型病毒性肝炎患者150例,按随机数表方式分组,其中恩替卡韦单一治疗的为对照组(n=75)、联合异甘草酸镁治疗的为观察组(n=75),比较两组患者临床疗效,并检测治疗前后AST、ALT与TBIL水平评估肝功能改善情况,最后再记录比较两组的不良反应状况。结果观察组临床治疗有效率为94.67%,高于对照组的80.00%,差异有统计学意义(χ^(2)=7.292,P<0.05)。两组治疗前各肝功能指标水平对比,差异无统计学意义(P>0.05);治疗后两组AST、ALT、TBIL水平均明显下降,且观察组各水平较对照组更低,差异有统计学意义(P<0.05)。观察组与对照组患者不良反应发生率对比,差异无统计学意义(P>0.05)。结论对慢性乙型病毒性肝炎患者采取异甘草酸镁联合恩替卡韦治疗,可取得更好的临床疗效,可改善肝功能,同时无明显不良反应,值得推广。

Objective To investigate the clinical efficacy of magnesium isoglycyrrhizinate combined with entecavir in the treatment of chronic hepatitis B and the improvement of liver function indicators in patients.Methods A total of 150 patients with chronic hepatitis B were selected from Nanjing Liuhe Hospital from January 2018 to December 2022.They were divided into groups according to the random number table,among which the single treatment of entecavir was the control group(n=75),and the treatment combined with magnesium isoglycyrrhizinate was the observation group(n=75).The clinical efficacy of the two groups was compared,and the levels of AST,ALT and TBIL were detected before and after treatment to evaluate the improvement of their liver function,and finally the adverse reactions of the two groups were recorded and compared.Results The overall clinical curative effect rate in the observation group was 94.67%,which was higher than 80.00%in the control group,the difference was statistically significant(χ^(2 )=7.292,P<0.05).There was no statistically significant difference in the levels of liver function indexes between the two groups before treatment(P>0.05).Before treatment,the levels of AST,ALT,and TBIL in the two groups were significantly decreased,and the levels in the observation group were lower than those in the control group,the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusion Magnesium isoglycyrrhizinate combined with entecavir can achieve better clinical efficacy and improve liver function in patients with chronic hepatitis B.At the same time,there is no obvious adverse reaction,which is worthy of popularization.